Remote Care in People With Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

— NOR-Flare  

Official title:

Can Machine Learning and Patient-reported Outcomes be Used in Remote Care in People With Rheumatic Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05496855
• Other study ID #: REK 457358
• Status: Recruiting
• Phase: N/A
• Start date: September 29, 2022
• Est. completion date: October 14, 2028

Study information

• Verified date: November 2022
• Source: Diakonhjemmet Hospital
• Contact: Anne Therese Tveter, PhD
• Phone: 91115550
• Email: AnneTherese.Tveter[@]diakonsyk.no
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a 24-months, non-inferiority randomized, controlled trial with two parallel arms to determine if a new follow-up strategy for patients with RA is non-inferior in maintaining comprehensive disease control measured as simultaneous maintenance of structural, functional and clinical treatment target at 2-year follow-up compared to the conventional follow-up regimen with regular hospital visits.

Description:

The study will include Norwegian adult males and females with rheumatoid arthritis. Eligible patients that consent to participation will be randomized to two groups:

• Control group: conventional follow-up strategy with blood tests, patient-reported outcomes (PROs), and pre-scheduled visits at the hospital every 6th month.

• Remote monitoring: monthly remote monitoring of PROs and triage of patients using an algorithm will guide healthcare providers in scheduling patients for a video consultation or face-to-face hospital visits.

Participants will be followed for 24 months. Primary outcome is proportionn maintaining comprehensive disease control measured as simultaneous maintenance of structural, functional and clinical treatment target at 2-year follow-up1.

• Structural: Assessed with radiographs of hands and feet according to the van der Heijde modified Sharpe score (subscores for erosions (0-280) and joint space narrowing (0-168)), with a total range of 0-448. Maintenance of structural treatment target is defined as change in total score <1 unit/year (<2 units from inclusion to 2-year follow-up).

• Functional: Measured by Modified Health Assessment Questionnaire (MHAQ) measured on a scale from 0.00 to 3.00, where a change of 0.25 is considered clinical important3. Maintenance of functional treatment target is defined as a worsening <0.25 from inclusion to 2-year follow-up.

• Clinical: Measured by DAS28, categorized into remission (<2.6), low disease activity (2.6 to ≤3.2), moderate disease activity (3.2 to ≤5.1) and high disease activity (>5.1). Maintenance of clinical treatment target is defined disease activity category at 2-year follow-up ≤ baseline category.

We will use a 15% non-inferiority margin.

The study will comprise an internal pilot study the first 6 months for all participants in the intervention group.

The study will also include qualitative research including semi-structured interviews and observations of patients in the intervention group and health professionals involved in the study. The interviews will explore experiences with remote monitoring and video consultations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 228
• Est. completion date: October 14, 2028
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or non-pregnant, non-nursing female =18 years of age at screening

• Patients with a diagnosis of RA who fulfil the 2010 ACR/EULAR diagnostic criteria24 (see Appendix 5, 10.4)

• Medical treatment with cs/ts/bDMARDs (incl. prednisolone) considered stable by the healthcare provider the last 6 months

• Low disease activity or remission (CDAI<10 / DAS28<3.2) at inclusion

• <2 swollen joints

• Not deemed inappropriate for remote monitoring by the healthcare provider

• Capable of understanding and signing an informed consent form

• Access to a smartphone or tablet

• Able to speak and understand Norwegian language

Exclusion Criteria:

Medical conditions:

• Major co-morbidities, such as severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV), severe respiratory diseases, and/or cirrhosis.

• Indications of active tuberculosis (TB)

• Treated with intravenous DMARD (e.g., rituximab and infliximab)

Diagnostic assessments:

• Abnormal renal function, defined as serum creatinine >142 µmol/L in female and >168 µmol/L in male, or glomerular filtration rate (GFR) <40 mL/min/1.73 m2

• Abnormal liver function (defined as Aspartate Transaminate (AST)/Alanine Transaminase (ALT) >3 x upper normal limit), active or recent hepatitis

• Leukopenia and/or thrombocytopenia

Other:

• Pregnancy and/or breastfeeding (current at screening or planned within the duration of the study)

• Severe psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible.

• Deemed unsuitable for remote monitoring by medical doctor

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Other:
• Conventional follow-up
Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
• Remote monitoring
The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for "tasks" (e.g., self-reporting PROs or registering results from blood tests) every month. A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention.

Locations

Country	Name	City	State
Norway	Diakonhjemmet Hospital	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Diakonhjemmet Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion maintaining comprehensive disease control	Comprehensive disease control measured as simultaneous maintenance of structural, functional and clinical treatment target at 2-year follow-up.; Structural: Radiographs of hands and feet according to the van der Heijde modified Sharpe score, with a total range of 0-448. Maintenance of structural treatment target is defined as change in total score <1 unit/year (<2 units from inclusion to 2-year follow-up).; Functional: Modified Health Assessment Questionnaire (MHAQ) measured on a scale from 0.00 to 3.00, where a change of 0.25 is considered clinical important. Maintenance of functional treatment target is defined as a worsening <0.25 from inclusion to 2-year follow-up.; Clinical: DAS28, categorized into remission (<2.6), low disease activity (2.6 to =3.2), moderate disease activity (3.2 to =5.1) and high disease activity (>5.1). Maintenance of clinical treatment target is defined disease activity category at 2-year follow-up = baseline category.	Baseline and 2 years
Secondary	Change in joint damage progression	Joint damage progression from inclusion to 2-year follow-up assessed with radiographs of hands and feet according to the van der Heijde modified Sharpe score (subscores for erosions (0-280) and joint space narrowing (0-168)), with a total range of 0-448. Measured as a continuous variable.	Baseline and 2 years
Secondary	Self-reported disease activity (intervention group)	Measured with patient global assessment of disease activity (0-10 scale, 0=no disease activity), estimated as change across all timepoints	Monthly until 2 years
Secondary	Self-reported disease activity (control group)	Measured with patient global assessment of disease activity (0-10 scale, 0=no disease activity), estimated as change across all timepoints	Baseline, 6 months, 12 months, 18 months and 2 years
Secondary	Health-related quality of life	Measured with EQ5D-5L, 5 questions used to calculate an utility score (0-1, 1= best health), assessed as a total score across all timepoints	Baseline, 6 months, 12 months, 18 months and 2 years
Secondary	Proportion in remission/low disease activity (CDAI)	Measured with CDAI (patient global assessment of disease activity, number of tender and swollen joints, physician assessment of disease activity). Remission/low disease activity defined as CDAI <10.	Baseline and 2 years
Secondary	Proportion in remission/low disease activity (DAS28)	Measured with DAS28 (patient global assessment of disease activity, CRP/ESR, number of tender and swollen joints). Remission/low disease activity defined as DAS28 <3.2.	Baseline and 2 years
Secondary	Disease activity in conjunction with consultation (DAS28)	Measured with DAS28 (patient global assessment of disease activity, CRP/ESR, number of tender and swollen joints).; DAS28 score: <2.6= remission; 2.6-<3.2=low disease activity; 3.2 -5.1= moderate disease activity; >5.2= high disease activity	Any consultation from baseline to 2 years
Secondary	Disease activity in conjunction with consultation (CDAI)	Measured with CDAI (patient global assessment of disease activity, number of tender and swollen joints, physician assessment of disease activity).; CDAI score: <=2.8 = remission; >2.8 - <=10 = low disease activity; >10 - <=22 = moderate disease activity; >22 = high disease activity	Any consultation from baseline to 2 years
Secondary	Health care utilization	Costs related to self-reported healthcare use in primary and secondary health care. Patients will be asked if they have been seeking healthcare (yes/no), if yes, they will be asked to specify type of healthcare use and time used. This information will also be collected from national register data.	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Patient-reported disease flares (intervention group)	Patient-reported experience of a significant worsening of symptoms (reflecting a flare in disease activity), response options: no, yes, uncertain. If yes or uncertain, they will be asked which date the flare occurred and the number of days it lasted.	Every month until 2 years
Secondary	Patient-reported disease flares (control group)	Patient-reported experience of a significant worsening of symptoms (reflecting a flare in disease activity), response options: no, yes, uncertain. If yes or uncertain, they will be asked which date the flare occurred and the number of days it lasted.	6 months, 12 months, 18 months, 2 years
Secondary	Adverse events	Number of adverse events, serious adverse events, and withdrawals because of adverse events.	Through study completion, maximum 2 years
Secondary	Number of consultations/contacts at the hospital	Reported by research nurse or study doctor when in contact with a patient.	From baseline to 2 years
Secondary	Activity impairment (intervention group)	Item no.6 from Work Productivity and Activity Impairment (WPAI): self-reported activity impairment on a NRS 0-10; higher value indicate worse outcome.	Baseline and monthly until 2 years
Secondary	Activity impairment (control group)	Item no.6 from Work Productivity and Activity Impairment (WPAI): self-reported activity impairment on a NRS 0-10; higher value indicate worse outcome.	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Costs related to hospital visits	Self-reported travel distance (km and time) and way of transport (walking, bicycle, privat car, public transportation, taxi, airplane, other) in conjunction with consultation at the hospital	Baseline
Secondary	The need to take time off for hospital visits or video consultation	If in paid work, the need to take time off from work is indicated as yes or no.	Baseline
Secondary	C-Reactive Protein (CRP) (intervention group)	Blood test at hospital or general practitioner	Baseline, 3, 6, 9, 12, 15, 18, 21 months and 2 years
Secondary	C-Reactive Protein (CRP) (control group)	Blood test at hospital or general practitioner	Baseline, 6 months, 12 months, 18 months and 2 years
Secondary	C-Reactive Protein (CRP) (intervention group)	Blood test measured at home in a subgroup among the intervention group	Monthly until 2 years
Secondary	Modified Health Assessment Questionnaire (MHAQ)	8 question concerning physical function, scored from 0 (no problems) to 3 (impossible to perform)	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	PROMIS Physical function	4 questions concerning physical function measured on a 5 point Likert scale	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Pain (intervention group)	Self-reported pain measured on a 11-point NRS (0=no pain; 10=worst possible pain)	Baseline and monthly until 2 years
Secondary	Pain (control group)	Self-reported pain measured on a 11-point NRS (0=no pain; 10=worst possible pain)	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Joint pain (intervention group)	Self-reported joint pain measured on a 11-point NRS (0=no joint pain; 10=worst possible joint pain)	Baseline and monthly until 2 years
Secondary	Joint pain (control group)	Self-reported joint pain measured on a 11-point NRS (0=no joint pain; 10=worst possible joint pain)	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Sleep impairment	1 item from Pittsburgh Sleep Quality Index, self-reported sleep impairment in last month due to pain with 4 response categories ranging "Not during the past month" to "Three or more times a week" ; higher value indicate worse outcome.	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Medication use	Medication, contomitant medication and any change in medication during the study period	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Swollen joint count	Physician count of swollen joints; MCP 1-5, PIP 1-5, wrist, elbows, shoulders, ankles, MTP 1-5, at regular visits, extra visits, withdrawls, early discontinuation	Baseline, any hospital visits, 2 years
Secondary	Tender joint count	Physician count of tender joints; MCP 1-5, PIP 1-5, wrist, elbows, shoulders, ankles, MTP 1-5, at regular visits, extra visits, withdrawls, early discontinuation	Baseline, any hospital visits, 2 years
Secondary	Extra visits, telephone and video consultations	Number of extra visits to the hospital or video consultations with a healthcare provider	Through study completion, maximum 2 years
Secondary	Withdrawals/early discontinuation	Number of withdrawals/early discontinuation	Through study completion, maximum 2 years
Secondary	Physical activity	3 questions assessing frequency, intensity and duration of physical activity last week	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Fatigue	Fatigue last week measured on an 11-point NRS (0=no fatigue, 10=worst possible fatigue)	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	Patient acceptable symptom state	one question assessing the patient acceptable symptom state last week, 5 response options from very good to very bad.	Baseline, 6 months, 12 months, 18 months, 2 years
Secondary	eHealth literacy	eHEALS questionnaire, 9 items measured on a 5 point Likert scale, with higher score indicating better health literacy	Baseline
Secondary	Patient-reported self-efficacy for using different digital devices, secure login and digital health services	Self-efficacy/confidence in using smartphone, tablet, computer, app's, secure login and digital health services. 6 items with Likert scale response categories: Never used, Very bad, Bad, Neither good nor bad, Good, Very good. Score range 1-5; higher scores indicate higher self-efficacy.	Baseline
Secondary	Patient satisfaction with care	1 item with five point response options ranging from "Very satisfied" to "Very dissatisfied", higher value indicate better outcome	Baseline, 6 months, 12 months, 18 months, 2 year
Secondary	Patient satisfaction with remote monitoring	Telehealth usability questionnaire (TUQ) 21 items scored from 1-7, higher score indicate higher satisfaction with telehealth	2 years